Merger Approved - Huge Drug Company & Dirt Cheap
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Today, news that the merger with Upjohn was approved hit the news wires.
bizjournals.com/pittsburgh/news/2020/06/30/mylan-shareholders-approve-upjohn-merger.html
Mylan is in my opinion, one of the cheapest drug stocks in the sector at current levels.
The stock currently trades at only 4x projected 2020 and 2021 earnings.
The stock should be upwards of $25 to $30 a share with the merger approval.
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Today, news that the merger with Upjohn was approved hit the news wires.
bizjournals.com/pittsburgh/news/2020/06/30/mylan-shareholders-approve-upjohn-merger.html
Mylan is in my opinion, one of the cheapest drug stocks in the sector at current levels.
The stock currently trades at only 4x projected 2020 and 2021 earnings.
The stock should be upwards of $25 to $30 a share with the merger approval.
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.